Information Provided By:
Fly News Breaks for May 20, 2015
BMRN, SRPT
May 20, 2015 | 09:05 EDT
Roth Capital hiked its price target on Sarepta (SRPT) after the company announced, following its meeting with the FDA, that it plans to submit a rolling NDA for eteplirsen. The firm says that BioMarin's (BMRN) decision to not yet initiate new studies on its DMD treatment has placed Sarepta in the pole position. The firm keeps a Buy rating on Sarepta.
News For SRPT;BMRN From the Last 2 Days
There are no results for your query SRPT;BMRN